[
  {
    "ts": null,
    "headline": "Assessing Biogen (BIIB) Valuation After China Accepts LEQEMBI Subcutaneous License Application",
    "summary": "Eisai and Biogen (BIIB) recently reported that Chinese regulators accepted a Biologics License Application for a subcutaneous version of LEQEMBI, a development that brings attention to Biogen’s current valuation and risk reward profile. See our latest analysis for Biogen. The LEQEMBI milestone lands at a time when Biogen’s 90 day share price return of 15.67% contrasts with a flat year to date share price picture and a mixed longer history, with a 1 year total shareholder return of 14.03% but...",
    "url": "https://finnhub.io/api/news?id=387ce5f0d5dd57316f7a3145fcc0c9881aceb574b66b9496728dd5f5f2545212",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767708814,
      "headline": "Assessing Biogen (BIIB) Valuation After China Accepts LEQEMBI Subcutaneous License Application",
      "id": 138000722,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Eisai and Biogen (BIIB) recently reported that Chinese regulators accepted a Biologics License Application for a subcutaneous version of LEQEMBI, a development that brings attention to Biogen’s current valuation and risk reward profile. See our latest analysis for Biogen. The LEQEMBI milestone lands at a time when Biogen’s 90 day share price return of 15.67% contrasts with a flat year to date share price picture and a mixed longer history, with a 1 year total shareholder return of 14.03% but...",
      "url": "https://finnhub.io/api/news?id=387ce5f0d5dd57316f7a3145fcc0c9881aceb574b66b9496728dd5f5f2545212"
    }
  },
  {
    "ts": null,
    "headline": "Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China",
    "summary": "If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the initiation of treatment for this progressive, relentless diseaseTOKYO and CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) f",
    "url": "https://finnhub.io/api/news?id=0f89eef66f31a5356fa4448456943f91a24c282fa172305eaa03319b51771116",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767661200,
      "headline": "Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China",
      "id": 137995641,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the initiation of treatment for this progressive, relentless diseaseTOKYO and CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) f",
      "url": "https://finnhub.io/api/news?id=0f89eef66f31a5356fa4448456943f91a24c282fa172305eaa03319b51771116"
    }
  }
]